Amphiphilic polymer
US-10328024-B2 · Jun 25, 2019 · US
US10857099B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10857099-B2 |
| Application number | US-201916404889-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 7, 2019 |
| Priority date | Nov 25, 2015 |
| Publication date | Dec 8, 2020 |
| Grant date | Dec 8, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present application relates to an amphiphilic polymer and a method of preparing the same. Furthermore, the present application relates to a micelle including a drug encapsulated by the amphiphilic polymer and a composition including the same. The amphiphilic polymer according to the present application has excellent drug encapsulation properties as well as good dispersion properties in an aqueous solution.
Opening claim text (preview).
What is claimed is: 1. A micelle comprising: an amphiphilic polymer, comprising: a first block (A); and a second block (B) which is phase-separated from the first block (A) and includes a polymerization unit (B1) of an acrylic monomer or vinyl-based monomer of which a homopolymer has a solubility parameter of less than 10.0 (cal/cm 3 ) 1/2 and a polymerization unit (B2) of a polymerizable monomer having a functional group which is capable of forming a hydrogen bond, wherein a weight ratio (B1:B2) of the polymerization unit (B1) of an acrylic monomer or vinyl-based monomer of which a homopolymer has a solubility parameter of less than 10.0 (cal/cm 3 ) 1/2 to the polymerization unit (B2) of a polymerizable monomer having a functional group which is capable of forming a hydrogen bond in the second block (B) is in a range of 1:9 to 9:1, and a drug encapsulated by the amphiphilic polymer, wherein the second block (B) of the amphiphilic polymer is adjacent to the drug, wherein the drug includes an insoluble biologically active substance, wherein the insoluble biologically active substance is one or more selected from the group consisting of genistein, daidzein, cucurbitacin, prangenidin and a derivative thereof, wherein the vinyl-based monomer is a compound represented by the following Formula 3 or 4: where, in Formula 3, X is a nitrogen atom or an oxygen atom, Y is a carbonyl group or a single bond, R 3 and R 5 each independently represent hydrogen or an alkyl group, or R 3 and R 5 are connected to each other to form an alkylene group, and R 4 is an alkenyl group, provided that when X is an oxygen atom, R 3 is not present; where, in Formula 4, R 6 , R 7 and R 8 each independently represent hydrogen or an alkyl group, and R 9 is a cyano group or an aromatic substituent. 2. The micelle of claim 1 , wherein the first block (A) includes a polymer having a solubility parameter of 10.0 (cal/cm 3 ) 1/2 or more. 3. The micelle of claim 1 , wherein the first block (A) includes at least one polymer selected from the group consisting of a polyethylene glycol, a polyethylene glycol-propylene glycol copolymer, a polyvinylpyrrolidone and a polyethyleneimine. 4. The micelle of claim 1 , wherein the acrylic monomer is a compound represented by the following Formula 1 or 2: where, in Formulas 1 and 2, Q is hydrogen or an alkyl group, in Formula 1, B is a linear or branched alkyl group with one or more carbon atoms, an alicyclic hydrocarbon group, an aromatic substituent or a carboxyl group, and in Formula 2, R 1 and R 2 each independently represent hydrogen, a linear or branched alkyl group with one or more carbon atoms, an alicyclic hydrocarbon group, or an aromatic substituent. 5. The micelle of claim 4 , wherein, in Formula 1, Q is hydrogen or an alkyl group with 1 to 4 carbon atoms, and B is an alkyl group with one or more carbon atoms or an alicyclic hydrocarbon group with 6 to 12 carbon atoms. 6. The micelle of claim 1 , wherein the functional group is a hydroxyl group, an amine group, a nitro group, an amino group, an imide group, an alkoxysilane group or a cyano group. 7. The micelle of claim 1 , wherein a block ratio (A:B) of the first block (A) and the second block (B) is different. 8. The micelle of claim 1 , wherein a block ratio (A:B) of the first block (A) to the second block (B) is in a range of 1:9 to 9:1. 9. The micelle of claim 1 , wherein a block ratio (A:B) of the first block (A) to the second block (B) is in a range of 3:7 to 7:3. 10. The micelle of claim 1 , wherein an average particle size is in a range of 1 to 10,000 nm. 11. A composition for preparing a particle, comprising the micelle of claim 1 . 12. A pharmaceutical or cosmetic composition, comprising the micelle of claim 1 . 13. The pharmaceutical or cosmetic composition of claim 12 , which is in the form of water-in-oil or oil-in-water emulsion.
condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} · CPC title
Preparations for care of the skin · CPC title
Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} · CPC title
Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms · CPC title
Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule (on to polymers modified by introduction of unsaturated end groups C08F290/02) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.